-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Fnzz4Fo15v4GdEd+cLQ5I029LmDHy6q1GYvFCLWy7C99kC9F5IlV3gH9hpRxtFyt KaiAGk/fZ5IDTg1e4eiiyA== 0001179110-05-006466.txt : 20050323 0001179110-05-006466.hdr.sgml : 20050323 20050323200021 ACCESSION NUMBER: 0001179110-05-006466 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20050310 FILED AS OF DATE: 20050323 DATE AS OF CHANGE: 20050323 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIPID SCIENCES INC/ CENTRAL INDEX KEY: 0000071478 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 430433090 STATE OF INCORPORATION: AZ FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 925-249-4000 MAIL ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 FORMER COMPANY: FORMER CONFORMED NAME: NZ CORP DATE OF NAME CHANGE: 20000810 FORMER COMPANY: FORMER CONFORMED NAME: NEW MEXICO & ARIZONA LAND CO DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MALTAIS JO-ANN B CENTRAL INDEX KEY: 0001162528 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-00497 FILM NUMBER: 05700173 BUSINESS ADDRESS: STREET 1: 7068 KOLL CENTER PARKWAY STREET 2: SUITE 401 CITY: PLEASANTON STATE: CA ZIP: 94566 BUSINESS PHONE: 9252494000 4/A 1 edgar.xml FORM 4/A - X0202 4/A 2005-03-10 2005-03-14 0 0000071478 LIPID SCIENCES INC/ LIPD 0001162528 MALTAIS JO-ANN B 7068 KOLL CENTER PARKWAY SUITE 401 PLEASANTON CA 94566-3111 0 1 0 0 VP, Scientific Affairs Stock Option (right to buy) 3.7 2005-03-10 4 A 0 23238 3.7 A 2015-03-09 Common Stock 23238 209140 D The options shall fully vest and be exercisable upon approval by the Federal Drug Administration ("FDA") of the Company's Investigational Device Exemption relating to selective HDL Delipidation, provided that such FDA approval occurs on or before March 10, 2006. If FDA approval of such application has not been granted by March 10, 2006, the options will terminate on such date. This amendment is being filed solely to correct footnote (1) above which explains the manner in which the reported options will vest and be exercisable. By Sandra Gardiner, as Attorney-in-Fact on behalf of Jo-Ann B. Maltais, Vice President of Scientific Affairs 2005-03-23 EX-24 2 exh24poajm.txt Power of Attorney This will confirm that I have granted each of the individuals listed below the authority to, on my behalf, execute and file the Statement of Changes in Beneficial Ownership of Securities (Form 4) and the Annual Statement of Beneficial Ownership of Securities (Form 5), both filed pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, as my Attorney In Fact. Such power of attorney shall remain in full force and effect until either (i) I am no longer subject to the reporting requirements under Section 16 of the Securities Act of 1933, as amended or (ii) I have provided you with written notice withdrawing this authority. The individuals who are authorized to act as my Attorney-In-Fact under this Power of Attorney are as follows: Deborah S. Lorenz Sandra Gardiner This Power of Attorney is effective immediately upon filing with the Securities Exchange Commission and, for purpose of my future Section 16 reports, replaces and revokes any and all other Powers of Attorney previously filed by me. Very truly yours, /s/ Jo-Ann B. Maltais _____________________ Jo-Ann B. Maltais Date: March 14, 2005 -----END PRIVACY-ENHANCED MESSAGE-----